Michael Döring

Michael Döring

Auto-generated profile, based on publicly available information

Michael Döring

Electrophysiology, Heart Center Leipzig, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CVChristian Veltmann
Christian Veltmann
DDDavid Duncker
David Duncker
MDMichael Doering
Michael Doering
SGSiva Gummadi
Siva Gummadi
MRMichael Robertson
Michael Robertson
LMLars S Maier
Lars S Maier
In patients with de novo heart failure with reduced ejection fraction (HFrEF), improvement of left ventricular ejection fraction (LVEF) is expected to occur when started on guideline-recommended medical therapy. However, improvement may not be completed within 90 days. Patients with HFrEF and LVEF ≤ 35% prescribed a wearable cardioverter-defibrillator between 2017 and 2022 from 68 sites were enrolled, starting with a registry phase for 3 months and followed by a study phase up to 1 year. The primary endpoints were LVEF improvement > 35% between Days 90 and 180 following guideline-recommended medical therapy initiation and the percentage of target dose reached at Days 90 and 180. A total of 598 patients with de novo HFrEF [59 years (interquartile range 51–68), 27% female] entered the study phase. During the first 180 days, a significant increase in dosage of beta-blockers, renin–angiotensin system inhibitors, and mineralocorticoid receptor antagonists was observed (P < .001). At Day 90, 46% [95% confidence interval (CI) 41%–50%] of study phase patients had LVEF improvement > 35%; 46% (95% CI 40%–52%) of those with persistently low LVEF at Day 90 had LVEF improvement > 35% by Day 180, increasing the total rate of improvement > 35% to 68% (95% CI 63%–72%). In 392 patients followed for 360 days, improvement > 35% was observed in 77% (95% CI 72%–81%) of the patients. Until Day 90, sustained ventricular tachyarrhythmias were observed in 24 wearable cardioverter-defibrillator carriers (1.8%). After 90 days, no sustained ventricular tachyarrhythmia occurred in wearable cardioverter-defibrillator carriers. Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement > 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy. Summary of design and results of Heart Failure Optimization study. Median left ventricular ejection fraction and percentage of patients with left ventricular ejection fraction > 35% at baseline, Days 90, 180, and 360. GRMT, guideline-recommended medical therapy; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; WCD, wearable cardioverter-defibrillator.

18 October 2017 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
SHSebastian Hilbert
Sebastian Hilbert
CJCosima Jahnke
Cosima Jahnke
SLSusanne Loebe
Susanne Loebe
SOSabrina Oebel
Sabrina Oebel
AWAlexander Weber
Alexander Weber
IPIngo Paetsch
Ingo Paetsch
To prospectively determine evaluability of routine cardiovascular magnetic resonance (CMR) diagnostic modules in a referral population of implanted rhythm device all-comers, and to establish a device-dependent CMR imaging strategy to achieve optimal image quality. One hundred and twenty-eight patients with cardiac implantable electronic devices [insertable cardiac monitoring system, n = 14; implantable loop-recorder, n = 21; pacemaker, n = 31; implantable cardioverter-defibrillator (ICD), n = 50; and cardiac resynchronization therapy defibrillator (CRT-D), n = 12] underwent clinically indicated CMR at 1.5 T. CMR protocols were tailored to the clinical indication and consisted of cine, perfusion, T1-/T2-weighted, late-gadolinium enhancement (LGE), 3D angiographic, and post-contrast cine spoiled gradient echo (SGE) scans. Image quality was determined using a 4-grade visual score per myocardial segment. Segmental evaluability was strongly influenced by device type and location with the highest proportion of non-diagnostic images encountered in the presence of ICD/CRT-D systems. Cine steady-state free-precession (SSFP) imaging was found to be mostly non-diagnostic in ICD/CRT-D patients, but a significant improvement of image quality was demonstrated when using SGE sequences with a further incremental improvement post-contrast resulting in an overall four-fold higher likelihood of achieving good image quality. LGE scans were found to be non-diagnostic in about one-third of left-ventricular segments of ICD/CRT-D patients but were artefact-free in > 94% for all other device types. Device type and location constitute the main independent predictors of CMR image quality and thus, need to be considered during protocol adaptation. Most notably, post-contrast SGE cine imaging proved superior to conventionally used SSFP sequences. Thus, following the proposed device-dependent CMR imaging strategy, diagnostic image quality can be achieved in the majority of device patients.

8 December 2014 in EP Europace
Verified
Journal Article
Open access
PDF file
KBKerstin Bode
Kerstin Bode
OBOle-A. Breithardt
Ole-A. Breithardt
MKManuela Kreuzhuber
Manuela Kreuzhuber
MMMeinhard Mende
Meinhard Mende
PSPhilipp Sommer
Philipp Sommer
ABAndreas Bollmann
Andreas Bollmann
Proper management of post-interventional pain relieves unwarranted patient distress and enhances patient satisfaction. There have been only a limited number of investigations into patient discomfort following electrophysiological interventions. This study aims to quantify pain after interventional procedures, including ablation of atrial fibrillation (AF) or ventricular tachycardia (VT), as well as implant or explant of pacemakers or implantable cardioverter defibrillators. One-hundred and two consecutive patients (mean age 66 years, 70 men) were asked to quantify post-interventional pain on a numeric rating scale (NRS 0–10) every 2 h during a period of 24 h after their intervention (49 ablations in deep propofol sedation, 53 device surgeries in local anaesthesia with mepivacaine 1%) and to specify the type of pain. Pain was classified as moderate to severe in case of NRS > 3. Post-operative pain medication included non-opioid and opioid analgesics as per the treating physicians' discretion. Sixty-one patients (60%) suffered from moderate-to-severe pain within the first 24 h after the procedure, despite the use of analgesics in 47 patients (46%). Pain was present in an early period (0–6 h) in 54% and in a late period (8–24 h) in 40% of patients. Patients complained of back pain (44%), pain at the site of the device pocket (39%), pain at the groin after puncture (7%), and pericarditic pain (5%). Multivariate analysis identified female gender (P = 0.046) associated with early post-interventional pain while age, diabetes mellitus, body mass index, type of intervention, and procedure time were not related to early or late post-interventional pain. The findings highlight the high prevalence and the poor predictability of moderate-to-severe post-interventional pain within the first 24 h after catheter ablation and cardiac device surgery procedures, despite the use of peri-interventional analgesics. These findings highlight the need for more careful pain assessment and management programmes.

6 July 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
MEMicaela Ebert
Micaela Ebert
NJNikolaus Jander
Nikolaus Jander
JMJan Minners
Jan Minners
TBThomas Blum
Thomas Blum
MDMichael Doering
Michael Doering
SRSergio Richter
Sergio Richter
Background: There is limited evidence of long‐term impact of right ventricular pacing on left ventricular ( LV ) systolic function in pacemaker recipients with preserved LV ejection fraction ( LVEF ). The objective of the study was to evaluate the outcome and echocardiographic course of baseline preserved LVEF in a large cohort of pacemaker recipients with respect to pacing indication and degree of right ventricular pacing. Methods and Results: We enrolled 991 patients (73±10 years, 54% male) with baseline normal (>55%) LVEF (n=791) or mildly reduced (41–55%) LVEF (n=200) who had paired echocardiographic data on LV systolic function recorded at implantation and last follow‐up. According to pacing indication, patients were divided into atrioventricular block group A (n=500) and sinus node disease group B (n=491). Main outcome measures were all‐cause mortality and deterioration of LV function ≥2 LVEF categories at last follow‐up. Patients were followed for an average of 44 months. Death from any cause occurred in 166 (17%), and deterioration of LV function ≥2 LVEF categories in 56 (6%) patients. There was no significant difference in outcome between group A and group B either in patients with normal LVEF or in those with mildly reduced LVEF . Mean percentage of right ventricular pacing was not predictive of outcome. Conclusions: In a large cohort of pacemaker recipients with predominantly normal LVEF , clinically relevant LV dysfunction develops rather infrequently. No significant difference in all‐cause mortality and development of severe LV dysfunction is observed between patients with atrioventricular block and sinus node disease. Accordingly, de novo biventricular pacing cannot be recommended for patients with preserved LVEF .

29 June 2018 in Deutsches Ärzteblatt international
Verified
Journal Article
Closed access
MDMichael Döring
Michael Döring
SRSergio Richter
Sergio Richter
GHGerhard Hindricks
Gerhard Hindricks
Cardiac implantable electronic devices (CIED), such as cardiac pacemakers (CP), implantable cardioverter defibrillators (ICD), and devices for cardiac resynchronization therapy (CRT), play an important role in the treatment of bradycardia...

31 January 2014 in EP Europace
Verified
Journal Article
Open access
PDF file
JKJedrzej Kosiuk
Jedrzej Kosiuk
EKEmmanuel Koutalas
Emmanuel Koutalas
MDMichael Doering
Michael Doering
PSPhilipp Sommer
Philipp Sommer
SRSascha Rolf
Sascha Rolf
ABAndreas Bollmann
Andreas Bollmann
The safety and efficacy of novel oral anticoagulants in patients with atrial fibrillation undergoing pacemaker or implantable cardioverter-defibrillator interventions have not been clearly defined. Therefore, we compared the incidence of bleeding and thrombo-embolic complications following cardiac rhythm device (CRD) implantations under dabigatran vs. rivaroxaban in a real-world cohort. We analysed 176 consecutive procedures performed in 93 patients treated peri-interventionally with dabigatran and 83 patients with rivaroxaban, respectively. Post-operative bleeding complications and thrombo-embolic events occurring within 30 days were compared. There were no significant differences in baseline characteristics between patients in the dabigatran and the rivaroxaban group. Most of the patients in both the groups received dual chamber or cardiac resynchronization devices (71 vs. 78%) as opposed to single-chamber systems (29 vs. 22%). In the dabigatran group, two (2%) bleeding complications (two pocket haematomas) were observed in comparison with four (5%, three pocket haematomas and one pericardial effusion) in the rivaroxaban group (P = 0.330). Three complications in the rivaroxaban group necessitated surgical intervention as opposed to none in the dabigatran group (P = 0.064). One case of a transient ischaemic attack occurred in the dabigatran group (P = 0.343). Bleeding and thrombo-embolic complications in patients treated with dabigatran or rivaroxban are rare. Further and larger studies are warranted to define the optimal anticoagulation management in patients with a need for oral anticoagulation and CRD interventions.